HR Execs on the Move

JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.